Newsroom

All News
  • All News
  • In the News
  • Press Releases
  • Publications
  • Events
Med-Tech

Rollie Carlson joins the Med-Tech podcast to discuss early diagnosis of sepsis

Med-Tech's Ian Bolland interviewed Rollie Carlson, CEO of Immunexpress, about the challenges of diagnosing sepsis and the technology that is being developed to tackle it. https://soundcloud.com/medtalkpodcast/developing-technology-for-faster-sepsis-diagnosis  
Immunexpress - the signature diagnostics for sepsis

SeptiCyte® RAPID Receives ICD-10-PCS Code from the U.S. Centers for Medicare & Medicaid Services (CMS)

This post originally appeared on Cision PR Newswire ICD-10-PCS code to provide accurate documentation of sepsis diagnosis for medical claims using SeptiCyte® RAPID SEATTLE and BRISBANE, Australia, Sept. 6, 2023 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostics company focused on improving outcomes for suspected sepsis patients, today announced that the U.S. Centers for Medicare...
Richard Brandon on PodcastDX, Episode 19

PodcastDX: Richard Brandon on Sepsis Rapid Test

Listen to the podcast: PodcastDX.com, episode S.14/E.19 Sepsis Rapid Test Show notes from the podcast Sepsis Rapid Test This week we will discuss a new rapid response test for Sepsis with one of the developers, Richard Brandon. Sepsis describes a syndrome that occurs when severe infection results in critical illness...
Immunexpress - the signature diagnostics for sepsis

Immunexpress and University Hospitals Cleveland Medical Center Present Quality Improvement Feasibility with SeptiCyte® RAPID at the 2023 American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Lab Expo

Immunexpress, Inc. 25 Jul, 2023, 16:30 ET SeptiCyte® RAPID, an in vitro diagnostic test intended to aid differentiating infection-positive (sepsis) from infection-negative systemic inflammation in patients suspected of sepsis, demonstrated good analytical performance SEATTLE and BRISBANE, Australia, July 25, 2023 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused...
Image from the CLP article

In the News: Why Better Sepsis Diagnosis Results in Better Outcomes

In Clinical Lab Products, Silvia Cermelli, PhD, and Prashant Wani, PhD say "The delay in sepsis diagnosis not only increases the risk of dying by as much as 8% every hour, but misdiagnosis leads to unnecessary use of strong antibiotic therapies causing health-related burdens on patients and economic burdens on...
Immunexpress - the signature diagnostics for sepsis

Immunexpress Announces Adoption of SeptiCyte® RAPID by FirstHealth of the Carolinas

SEATTLE and BRISBANE, Australia, July 20, 2023 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for patients suspected of sepsis, announced today the adoption of SeptiCyte® RAPID by FirstHealth of the Carolinas, a non-profit health system licensed for four hospitals in Pinehurst, Troy, Rockingham and Raeford, North Carolina. SeptiCyte RAPID will be available at FirstHealth...
Big Breakthrough podcast with Richard Brandon

Slice of Healthcare’s Big Breakthrough podcast features Richard Brandon, Chief Scientific Officer At Immunexpress

  From the Slice of Healthcare podcast notes: What you’ll get out of this episode: Richard’s background Overview of Immunexpress The impact of a lack of reliable sepsis diagnostics SeptiCyte technology What’s next? https://youtu.be/jGLXeCJsMA4
IDTransmission

In the news: A Diagnostic Dilemma

A sepsis thought leadership article from Richard Brandon PhD, CTO at Immunexpress has just been published in IDTransmission. Sepsis takes a heavy toll on society, causing millions of fatalities worldwide per year and costing upwards of US$50 billion yearly in the US alone. Sepsis can develop from viral, bacterial, and...
Healthcare IT Today

In the news: Immunexpress SeptiCyte in Healthcare IT Today

From the article Better Health Care Tests, Faster, by Andy Oram, posted on Healthcare IT Today More Accurate Detection of Sepsis Sepsis is one of the most dreaded hospital-spawned conditions: It’s common and can quickly be fatal. According to Dr. Rolland Carlson, CEO of Immunexpress, a sepsis diagnosis often takes...
Image from the CLP article

In the news: Why Better Sepsis Diagnosis Results in Better Outcomes at CLP

https://clpmag.com/disease-states/sepsis/why-better-sepsis-diagnosis-results-in-better-outcomes/ From the CLP article by By Silvia Cermelli, PhD, and Prashant Wani, PhD: Making a Breakthrough in Rapid Sepsis Diagnosis Immunexpress’s SeptiCyte RAPID measures host response to differentiate sepsis from non-infectious systemic inflammation (i.e., SIRS). It is an FDA cleared test for this purpose and has a one-hour turnaround...
Infection Today (logo)

In the news: Septicyte RAPID test mentioned in Infection Control Today

From the article in Infection Control Today SeptiCyte RAPID test Sepsis is an overwhelming immune response to infection that can be life-threatening. Immunexpress’ SeptiCyte RAPID test is meant to ensure the timely and accurate diagnosis of sepsis, which is critical to allow clinicians to rapidly make correct treatment decisions that...
Cision PR Newswire

Immunexpress to Present Data at ECCMID 2023 Indicating that SeptiCyte® RAPID Differentiates Sepsis from Non-Sepsis in Patients with Uncertain Initial Diagnosis

This post originally appeared on Cision PR Newswire SEATTLE and BRISBANE, Australia, April 5, 2023 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today a poster presentation at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) which evaluates the use of SeptiCyte® RAPID...

If you are a member of the media, please contact:

Scott Stachowiak
Russo Partners
(646) 942-5630
scott.stachowiak@russopartnersllc.com